On June 25, 2009, OraSure Technologies, Inc. (the "Company") issued a press release providing an update on clinical development programs and manufacturing issues recently experienced with respect to the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test. A copy of this press release is attached to this Current Report as Exhibit 99.1.

The information in this Current Report and attached Exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report or attached Exhibit.

(d) Exhibits

Exhibit
Number    Description
99.1      Press Release, dated June 25, 2009, providing an update on clinical
          development programs and manufacturing issues recently experienced with
          respect to the OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test.